Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ovarian Neoplasms × veliparib × Clear all

Phase

Phase 1 11 Phase 2 3 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Breast Neoplasms 1

Interventions

Paclitaxel 67 Carboplatin 56 Bevacizumab 28 liposomal doxorubicin 23 Topotecan 22 Gemcitabine 18 olaparib 16 Cisplatin 13 Doxorubicin 12 Drug Therapy 11 Taxes 10 niraparib 9 Docetaxel 6 Trabectedin 5 CP protocol 5 avelumab 4 atezolizumab 4 Immunoglobulin G 4 Ifosfamide 4 Hyperthermic Intraperitoneal Chemotherapy 4 Disulfides 4 Dexamethasone 4 Cyclophosphamide 4 Chemotherapy, Adjuvant 4 1-dodecylpyridoxal 4 trebananib 3 pembrolizumab 3 fluzoparib 3 dostarlimab 3 cediranib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02470585 2024-10-26

VELIA

AbbVie

Phase 3 Terminated

1,140 enrolled 29 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡